drugset / Trial / NCT05376566

Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections

NCT05376566 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Aim: This study will test whether treatment of central line-associated bloodstream infections (CLABSI) with hydrochloric acid lock therapy (HALT) can significantly reduce the risk of treatment failure (comprising failure to clear initial infection, relapse of infection, or reinfection) in patients treated for cancer or hematologic diseases. Study design: A multicentre, double-blinded, randomized controlled trial. Patient population: Patients (0-100 y) with cancer or a hematologic disorder and a CLABSI treated at Copenhagen University Hospital, Aarhus University Hospital, or Odense University Hospital, Denmark. Randomization: Patients are equally assigned (1:1) to receive either HALT or placebo (normal saline). In addition to the study intervention, patients in both arms will receive standard systemic antibiotic therapy. Sample size: A target population of 250 patients Statistical Analysis Plan is uploaded in "Study Documents"

Timeline

Start
2022-06-01
Primary completion
2026-03-01
Completion
2026-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrochloric Acid Small molecule 2 unknown Other

Indications

No indication recorded.